Medication info
Belmetec Plus Tablet 20/12.5 Milligrams

Belmetec Plus Tablet 20/12.5 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201100826 · Notified 2011.02.22 · Insurance code 643306020

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before administering this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, regardless of meals. Adjust the dose at intervals of 2~4 weeks based on the patient's blood pressure response. In patients taking high-dose hydrochlorothiazide monotherapy, and in patients with volume depletion or hyponatremia, concomitant use of olmesartan medoxomil or switching to this medicine (olmesartan medoxomil/hydrochlorothiazide) may result in a marked reduction in blood pressure. In such cases, the dose of hydrochlorothiazide should be reduced to 12.5mg before concomitant administration of olmesartan medoxomil. In elderly patients, start with the lowest dose and use caution when adjusting the dose, taking into account the patient's renal or cardiac function, comorbid conditions, and other concomitant medications. This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). In patients with more severe renal impairment, loop diuretics are preferable to thiazide diuretics; therefore, this medicine (olmesartan medoxomil/hydrochlorothiazide) should not be administered. Use of this medicine is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.
Child dose
The safety and efficacy in children have not been established.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Olmesartan Medoxomil and Hydrochlorothiazide are medications used to treat essential hypertension. If blood pressure control is insufficient with monotherapy, these two medications can be combined to lower blood pressure more effectively. This helps to manage blood pressure steadily and reduces the risk of complications arising from hypertension. Therefore, these medications play a vital role in the treatment of hypertension and assist in blood pressure control.

How to take

Adult dose

Before administering this medicine, it is recommended that the dose of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this medicine once daily, regardless of meals. Adjust the dose at intervals of 2~4 weeks based on the patient's blood pressure response. In patients taking high-dose hydrochlorothiazide monotherapy, and in patients with volume depletion or hyponatremia, concomitant use of olmesartan medoxomil or switching to this medicine (olmesartan medoxomil/hydrochlorothiazide) may result in a marked reduction in blood pressure. In such cases, the dose of hydrochlorothiazide should be reduced to 12.5mg before concomitant administration of olmesartan medoxomil. In elderly patients, start with the lowest dose and use caution when adjusting the dose, taking into account the patient's renal or cardiac function, comorbid conditions, and other concomitant medications. This medicine (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). In patients with more severe renal impairment, loop diuretics are preferable to thiazide diuretics; therefore, this medicine (olmesartan medoxomil/hydrochlorothiazide) should not be administered. Use of this medicine is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.

Child dose

The safety and efficacy in children have not been established.

Precautions

This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Patients allergic to the components in this medication or those with hypersensitivity to specific diuretics, severe kidney or liver dysfunction, pregnant or breastfeeding women should not take this medication. Patients with reduced blood volume, decreased kidney function, liver diseases, or specific heart conditions must exercise caution while taking this medication and require close monitoring by healthcare professionals. During the use of this medication, dizziness or hypotension may occur; if symptoms arise, one should lie down and rest and receive intravenous treatment if necessary. This medication can cause an imbalance of electrolytes in the blood, hence regular blood tests should be conducted to monitor potassium, sodium, and other levels. Particularly, this medication may make the skin sensitive to sunlight, so exposure to sunlight should be minimized, and any suspicious skin changes should be promptly discussed with a healthcare provider. Interactions with other medications may occur while taking this medication; therefore, patients must inform their healthcare provider of any other medications they are taking. Dizziness or drowsiness may be experienced, necessitating caution when driving or operating dangerous machinery. Women who are pregnant, planning to become pregnant, or breastfeeding should definitely consult with their healthcare provider before deciding to take this medication, and if necessary, should discontinue the medication or breastfeeding. The safety of this medication has not been established in children, so it is advisable not to administer it to children. Elderly patients may have reduced kidney or liver function; thus, they should start with the lowest dose and proceed with caution. In case of overdose, symptoms like hypotension and cardiac variations may occur, so immediate medical attention is necessary.

Side effects

Nausea, hyperuricemia, dizziness, upper respiratory infection, headache, urinary tract infection, chest pain, back pain, peripheral edema, vertigo, abdominal pain, dyspepsia, gastroenteritis, diarrhea, elevated AST, elevated GGT, elevated ALT, hyperlipidemia, increased creatine phosphokinase, hyperglycemia, arthritis, arthralgia, myalgia, cough, rash, hematuria, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, hair loss, pruritus, urticaria, rhabdomyolysis, acute renal failure, increased serum creatinine, palpitations, hypercholesterolemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, chronic malabsorption syndrome, intestinal vascular edema, autoimmune hepatitis, polydipsia, abdominal discomfort, constipation, abdominal colic, pancreatitis, jaundice, sialadenitis, dry mouth, gastric pain, fatigue, drowsiness, emotional blunting, restlessness, interstitial pneumonia, pulmonary edema, acute respiratory distress syndrome, orthostatic hypotension, arrhythmia, transient blurred vision, jaundice, choroidal effusion, hepatitis, acute cholecystitis, necrotizing vasculitis, vasculitis, cutaneous vasculitis, facial flushing, photosensitivity, acute kidney injury, interstitial nephritis, renal dysfunction, malaise, nasal congestion, erectile dysfunction, exacerbation of systemic lupus erythematosus, parathyroid dysfunction, muscle cramps, sensory abnormalities, frailty, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture and stored at room temperature between 1 to 25 degrees Celsius. Proper storage ensures the medication’s effectiveness is maintained and prevents degradation.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.